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ARTICLE
Nucleotide-Resolution Mapping of Topoisomerase-Mediated
and Apoptotic DNA Strand Scissions at or near an MLL
Translocation Hotspot
Marc-Edouard Mirault, Patrick Boucher, and Alain Tremblay
The emergence of therapy-related acutemyeloid leukemia (t-AML) has been associatedwithDNA topoisomerase II (TOP2)–
targeted drug treatments and chromosomal translocations frequently involving the MLL, or ALL-1, gene. Two distinct
mechanisms have been implicated as potential triggers of t-AML translocations: TOP2-mediated DNA cleavage and
apoptotic higher-order chromatin fragmentation. Assessment of the role of TOP2 in this process has been hampered by
a lack of techniques allowing in vivo mapping of TOP2-mediated DNA cleavage at nucleotide resolution in single-copy
genes. A novel method, extension ligation-mediated polymerase chain reaction (ELMPCR), was used here for mapping
topoisomerase-mediated DNA strand breaks and apoptotic DNA cleavage across a translocation-prone region of MLL in
human cells. We report the ﬁrst genomic map integrating translocation breakpoints and topoisomerase I, TOP2, and
apoptotic DNA cleavage sites at nucleotide resolution across an MLL region harboring a t-AML translocation hotspot.
This hotspot is ﬂanked by a TOP2 cleavage site and is localized at one extremity of a minor apoptotic cleavage region,
where multiple single- and double-strand breaks were induced by caspase-activated apoptotic nucleases. This cleavage
pattern was in sharp contrast to that observed ∼200 bp downstream in the exon 12 region, which displayed much
stronger apoptotic cleavage but where no double-strand breaks were detected and no t-AML–associated breakpoints were
reported. The localization and remarkable clustering of the t-AML breakpoints cannot be explained simply by the DNA
cleavage patterns but might result from potential interactions between TOP2 poisoning, apoptotic DNA cleavage, and
DNA repair attempts at speciﬁc sites of higher-order chromatin structure in apoptosis-evading cells. ELMPCR provides a
new tool for investigating the role of DNA topoisomerases in fundamental genetic processes and translocations associated
with cancer treatments involving topoisomerase-targeted drugs.
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The stabilization of DNA topoisomerase II (TOP2) cleavage
complexes by speciﬁc poisons converts this enzyme into
a potent genotoxin.1,2 Studies of DNA cleavage induced in
vivo by TOP2-targeted drugs, such as epipodophyllotoxins
(e.g., etoposide and teniposide) and anthracyclines (e.g.,
doxorubicin and epirubicin), are clinically very relevant
because these drugs are widely used to treat leukemias,
lymphomas, and various cancers, including breast and
ovarian cancers, but are increasingly suspected to be at
the origin of secondary cancers (reviewed by Pedersen-
Bjergaard and Rowley,3 Felix,4 and Pui and Relling5). A case
in point is the emergence of therapy-related acutemyeloid
leukemia (t-AML), which is frequently associated with the
use of TOP2-targeted drugs and can occur in up to 10%
of children who receive treatment for acute lymphoblastic
leukemia. These drugs are strongly suspected to induce
recurrent chromosomal translocations at speciﬁc loci,
some of which may persist in surviving cells and confer
a selective growth advantage to leukemogenic cells. Re-
current translocations observed in 33% of 511 therapy-
related acute leukemia or myelodysplastic syndrome cases
involved the myeloid-lymphoid (or mixed lineage) leu-
kemia gene (MLL, or ALL-1 [MIM 159555]) on chromo-
some 11 band q236 and in-frame fusion with 1 of 140
partner genes (reviewed by Rowley7). Virtually all MLL
translocation breakpoints are clustered in a particular re-
gion of the gene called the “breakpoint cluster region.”
MLL is a human homolog of the Drosophila gene trithorax,
a positive regulator of gene expression during develop-
ment. It encodes a histone H3 lysine 4–speciﬁc methyl-
transferase, which regulates target Hox gene expression.8
It is not required for initiation of gene activity but main-
tains transcriptional states through later stages of devel-
opment. Recombinant disruption of MLL may generate
fusion proteins leading to leukemic transformation,9
which strongly suggests that deregulation of Hox gene ex-
pression is critical for MLL-associated leukemogenesis.
Despite the strong epidemiological link supporting a
causative involvement of TOP2 in induction of t-AML–
associated translocations, the direct implication of TOP2
in this process has remained elusive. Although several
studies have tentatively localized drug-induced TOP2
cleavage sites at or close to translocation breakpoints,4,10,11
their identiﬁcation was based on homology to published
TOP2 “consensus sequences” or on in vitro cleavage of
cloned DNA by TOP2. The assumption that the in vitro
cleavage sites reﬂect genuine TOP2 cleavage sites in vivo
(in chromatin) has been challenged,12–14 and bona ﬁde lo-
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calization of in vivo TOP2 cleavage sites in the vicinity of
MLL translocation breakpoints, at nucleotide resolution,
has not yet been reported. On the other hand, higher-
order chromatin fragmentation occurring during drug-
induced apoptosis was proposed as an alternative mech-
anism for initiation of t-AML–associated chromosomal
translocations.15 In support of this, in vitro experiments
with cultured cells revealed that activation of apoptotic
effector nucleases alone was sufﬁcient to generate proleu-
kemogenic translocations and suggested that some of
thesemay persist in cells that evade apoptosis anddivide.16
Thus, it is not clear whether TOP2-mediated DNA strand
breaks or DNA cleavage produced by subsequently acti-
vated apoptotic nucleases is at the origin of the recurrent
chromosomal translocations observed in t-AML.
Although conventional ligation-mediated PCR (LMPCR)
is a powerful tool for genomic sequencing, in vivo foot-
printing of protein-DNA complexes, and mapping of var-
ious forms of DNA damage at genomic sites of interest
(reviewed by Pfeifer and Riggs17 and Drouin et al.18), the
scope of DNA-damage detection by LMPCR is intrinsically
limited to DNA lesions, which produce, directly or indi-
rectly, DNA strand breaks with 5′-phosphate (5′-P) termini
required for linker ligation. This limitation excludes the
use of LMPCR for detection of several DNA lesions, in-
cluding those mediated by type II and type IA DNA
topoisomerases, which generate transient DNA strand
breaks with enzyme-linked 5′ termini (reviewed by Liu1
and Wang2). The difﬁculty in mapping in vivo TOP2-me-
diated DNA cleavage at nucleotide resolution in single-
copy genes is highlighted by the absence of related
publications, despite the development of versatile meth-
ods such as single-strand ligation PCR19 and terminal
transferase–dependent PCR,20 which were primarily de-
signed to detect covalent adduct formation by DNA-dam-
aging agents.
In the present study, a different procedure, extension
LMPCR (ELMPCR), was used for genomic mapping of
DNA strand breaks that escape detection by conventional
LMPCR because of formation of 5′ termini different from
5′-P. We show that a combination of ELMPCR and LMPCR
is a powerful tool for genomic mapping of topoisomerase-
mediated strand breaks and apoptotic DNA cleavage at
single-nucleotide resolution in human cells. We report the
ﬁrst genomic map integrating translocation breakpoints
and drug-induced DNA cleavages mediated by TOP2, to-
poisomerase I (TOP1), or caspase-activated DNases at nu-
cleotide resolution across translocation-prone and appar-
ently translocation-exempt regions of the MLL gene.
Although a strong in vivo TOP2 cleavage site and a major
apoptotic cleavage region were identiﬁed in MLL exon 12,
both were localized 1200 bp downstream of a remarkable
cluster of t-AML–related translocation breakpoints located
in intron 11. This translocation hotspot was ﬂanked by
another TOP2 cleavage site and was localized within a
minor apoptotic cleavage region featuring multiple cas-
pase-dependent double-strand breaks (DSBs) not observed
in exon 12. Although the issue of the relationship of the
translocation breakpoints to DNA cleavage by TOP2 or an
apoptotic nuclease was not resolved, this study demon-
strates that ELMPCR provides an efﬁcient tool for high-
resolution mapping of in vivo TOP2 DNA cleavage sites.
This is of importance because cellular TOP2 cleavage sites
were found to be different from those observed in vitro
with puriﬁed enzyme or those predicted from putative
“consensus” sequences.
Material and Methods
Cell Culture and Treatments
Primary human skin ﬁbroblasts were grown in high-glucose/
HEPES Dulbecco’s modiﬁed Eagle’s medium (Sigma) supple-
mented with sodium pyruvate (0.11 g/liter), antibiotic antimy-
cotics, and 5% fetal bovine serum (FBS). HumanEpstein-Barr virus
(EBV)–transformed B-lymphoblastoid P6 cells, T-lymphoblastoid
CEM cells (ATCC line CCRF-CEM), and TOP2a-mutantCEM/VM-
1 cells deﬁcient in TOP2 activity21,22 were cultured in RPMI 1640
medium containing 10% FBS. Conﬂuent cultures of ﬁbroblasts
or of growing P6 or CEM cells were incubated in the presence of
etoposide (VP-16 [Novopharm], purchased as a physiologic so-
lution for patient treatment and diluted in medium), campto-
thecin (CPT) (Sigma), or CD95 antibody (clone CH11 [Upstate]),
which was added to the medium at concentrations indicated in
the ﬁgures. After medium removal at the end of treatment, the
cells were covered with or resuspended into 2 ml PBS and were
incubated for 15 min at 60C—to reverse TOP2- and TOP1-
mediated DNA cleavage—or were not incubated, before DNA iso-
lation. Of note, heat treatment at this temperature was sufﬁcient
to revert efﬁciently the topoisomerase-mediated DNA cleavages
observed in cells, in contrast to reversion of in vitro TOP2a cleav-
age reactions, which are reported to require a higher tempera-
ture.23 Alternatively, reversion was also performed by 30-min in-
cubation of drug-treated cells at 37C in the absence of drug and
in complete medium.
DNA Isolation
Minimizing artefactual background DNA damage during DNA
isolation is critical for maximizing (E)LMPCR detection of phys-
iologically relevant DNA cleavage. Genomic DNA was extracted
from intact cells, to avoid any possible enzymatic DNA cleavage
associated with cell fractionation. The resuspended cells were
lysed by addition of 2 ml of 2# lysis buffer and 11 ml of lysis
buffer (50 mM Tris-HCl [pH 7.4], 20 mM EDTA [pH 7.4], 1% SDS,
10 mM deferoxamine mesylate (Sigma), and 0.5 mg/ml proteinase
K) and were incubated overnight at 37C. To remove proteinase
K, protein salting-out was performed by addition of 2/5 volumes
of saturated NaCl to 1 volume of cell lysate, followed by mixing
and centrifugation for 15 min at 20,200 g; the DNA-containing
supernatant was recentrifuged at 20,200 g and was precipitated
with 2 volumes absolute ethanol (for 30 min at 70C and 15
min at 1,100 g at 4C). DNA pellets were rinsed once with 80%
ethanol andwere recentrifuged at 1,100 g.After complete removal
of the ethanol, wet DNA pellets were dissolved in 200 ml auto-
claved ultrapure water (PURELAB Ultra water puriﬁcation system
[Elga]). To remove RNA, each sample was incubated at 37C for
1 h in 300 ml of 10-mM Tris-HCl (pH 8.0), 1-mM EDTA (pH 8.0),
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Figure 1. Distinctive features of ELMPCR compared with those
of conventional LMPCR. LMPCR requires a 5′-phosphate (P) at the
5′ end of a genomic DNA break for linker ligation, in contrast to
ELMPCR, which involves ligation of an antilinker (with a sequence
complementary to the LMPCR linker) to the 3′-hydroxyl(OH) end
of a primer 1 extension product.
Figure 2. Comparison of efﬁciency of antilinkers terminated by
a 3′-phosphate-deoxycytidine or a 2′,3′-dideoxycytidine in ELMPCR
detection of topoisomerase-mediated DNA cleavage. The legend is
available in its entirety in the online edition of The American
Journal of Human Genetics.
and 0.17-mg/ml heat-treated DNase-free RNase A (Roche), fol-
lowed by addition of 300 ml of 2# proteinase K buffer (200 mM
NaCl, 50 mM EDTA [pH 8.0], 10 mM Tris-HCl [pH 8.0], 1% SDS,
and 1 mg/ml proteinase K [Invitrogen]) and incubation at 37C
for 1 h and 50C for 1 h. Proteinase K was removed by salting-
out (as described above) followed by phenol extraction. The phe-
nol quality is of critical importance for minimizing oxidative
damage to the DNA during extraction. We used pH-8.0 buffer-
equilibrated ultrapure phenol (MB grade [USB]) containing 0.1%
8-hydroxyquinoline (Sigma). The DNA was extracted with 1 vol-
ume of phenol-chloroform-isoamylalcohol (50:48:2), followed
by one chloroform extraction and ethanol precipitation (2 vol-
umes). After cooling at 70C for 30 min and centrifugation at
9,300 g for 5 min, DNA pellets were washed once with 80% eth-
anol, were resuspended in 400 ml TE (10-mM Tris-HCl and 1-mM
EDTA [pH 8.0]), and were reprecipitated overnight at20Cwith
2.5 volumes ethanol after addition of 40 ml of 5-M NaCl. After
one wash with 80% ethanol, wet DNA pellets were dissolved in
200 ml of 1-mM Tris-HCl (pH 8.0) for 48–72 h at 4C, including
gentle mixing by hand several times a day. After complete DNA
dissolution, residual traces of ethanol were eliminated by incu-
bation at 65C for 5 min (in open tubes). Note that DNA samples
were never put on vortex and were always treated so as to min-
imize DNA shearing, and they were not desiccated, to avoid ox-
idation and to facilitate DNA dissolution in aqueous buffers. The
DNA concentration (∼0.5 mg/ml) was measured by diphenylamine
assay and/or ﬂuorometry by use of a TKO-100 DNA ﬂuorometer
in accordance with the instructions of the manufacturer (Hoefer
Scientiﬁc Instruments).
LMPCR and ELMPCR
LMPCR was performed essentially by the method of Drouin et
al.,18 with the use of Pfu exo polymerase in the primer extension
step.24 The distinctive feature of ELMPCR is that a 5′-phospho-
rylated asymmetric “antilinker” is ligated to the 3′-OH termini of
the primer 1 extension products (ﬁg. 1). The long and short an-
tilinker oligonucleotides were 5′-P-GAATTCAGATCTCCCGGGT-
CACCGC-3′ and 5′-GATCTGAATTddC-3′ (Keystone Labs), respec-
tively, with the latter carrying a (2′,3′)-dideoxy-cytidine (ddC) or
a 3′-phosphate at the 3′ end, to prevent interlinker ligation. Sim-
ilar ELMPCR results were obtained with these two modiﬁed 3′
ends (ﬁg. 2). ELMPCR ampliﬁcation was done as for LMPCR, ex-
cept that the linker-primer concentration was doubled, to com-
pensate for the loss of single-strand linker-primer resulting from
annealing to residual complementary antilinker oligonucleotides.
LMPCR and ELMPCR reactions were run in a PTC-100 or PTC-
200 DNA engine (MJ Research). All primers (table 1) were selected
using computer programs as described elsewhere.18
Optimization of buffer and temperature conditions for primer 1 ex-
tension.—Optimal conditions of Pfu exo-mediated primer 1 ex-
tension were determined by testing which of the 12 buffers of
the Opti-Prime PCR Optimization Kit (Stratagene) or standard Pfu
buffer containing 2 mM or 4 mM MgSO4 gives the best yield of
expected PCR product generated by a pair of primers 1, by use
of 75 ng cellular DNA, 1.5 pmol of each sense and antisense
primer 1 to be used together, 250 mM of each dNTP, and 0.75 U
Pfu exo in 15 ml optimal buffer (in 0.2-ml tubes) across 25 PCR
cycles (at 95C for 60 s, average primer 1 annealing temperature
[Tm] for 60 s, and 74C for 60 s) following an initial step at 95C
for 5 min. After incubation at 74C for 10 min at the end, the
PCR products were analyzed on agarose gels. The optimal tem-
perature (Topt) was determined by running 12 PCR reactions with
the optimal buffer over a temperature gradient from the average
primer 1 Tm  4C to the average primer 1 Tm  11C, by use of
a PTC-200 equipped with a temperature gradient head (MJ
Research).
Primer 1 annealing.—Cellular DNA (1.6 mg) was incubated with
1.25 pmol primer 1 in 25 ml optimal buffer for 20 min at primer
1 Topt (table 1) after 3 min of incubation at 98C.
Primer 1 extension.—Primer 1 extension was performed at Topt
by addition of 5 ml (containing 1.5 mM of each dNTP and 1.5 U
Pfu exo) to the 25 ml of annealed DNA and incubation from Topt
to 74C at 0.1C temperature increase per second and for 10 min
at 74C, followed by a return to 4C, a cooling on ice, and a quick
spin. The asymmetric double-stranded linker and antilinker were
freshly prepared by annealing of the 25-mer oligonucleotides to
their respective complementary 11-mer oligonucleotides, as de-
scribed by Drouin et al.18
Ligation.—Ligation reactions were performed by addition of a
782 The American Journal of Human Genetics Volume 79 November 2006 www.ajhg.org
Table 1. Primers and Optimized Conditions Used
for Primer Extension and PCR Ampliﬁcation
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 3. Linear relationship between ELMPCR signal intensity
and the extent of TOP2-mediated DNA cleavage. The legend is
available in its entirety in the online edition of The American
Journal of Human Genetics.
45-ml ligation cocktail (containing, for 10 reactions, 15 ml of 1-M
dithiothreitol, 7.6 ml of 100-mM ATP, 7.6 ml of 1-M MgCl2, 7.6 ml
of 0.1-M spermidine, 9.2 ml BSA at 5 mg/ml, 16 ml of 2-M Tris-
HCl [pH 7.4], 50 ml linker or 10 ml antilinker at 20 pmol/ml, 6.6
ml T4 DNA ligase [5 U/ml; Roche], and H2O, to total 450 ml) to the
30-ml primer 1 extension mixtures and by incubation overnight
at alternating temperature cycles: 10C for 30 s and 22C for 30
s. The ligation reactions were stopped on ice by addition of 30
ml containing 28 ml of 7.5-M NH4OAc, 1 ml of 0.5-M EDTA, and
1 ml glycogen at 20 mg/ml and were transferred to 0.5-ml thick-
wall tubes. The DNA was precipitated by addition of 275 ml ice-
cold ethanol and centrifugation at 15,800 g for 20 min at 4C
(Microfuge). DNA pellets were rinsed once with 0.5 ml of 80%
ethanol, were centrifuged at 15,800 g for 8 min, and were resus-
pended in 25 ml H2O. The DNA solution was heated at 65C for
10 min (in open tubes).
Optimization of primer 2–mediated PCR ampliﬁcation.—Primers 2
used in this study are listed in table 1, with optimal buffer and
temperature conditions determined as follows and with pairs of
primer sets as indicated. Each optimal buffer was determined by
testing which of 10 Taq buffers supplemented with 2, 4, 6, 8, or
10 mM MgCl2 or with 2, 4, 6, 8, or 10 mM MgCl2 plus 15 mM
(NH4)2SO4 gives the best yield of expected PCR product, by use
of 1 mg cellular DNA, 10 pmol of each sense and antisense primer
2 to be used together, 200 mM of each dNTP, and 3 U Taq DNA
polymerase in 100-ml PCR reactions (in 0.5-ml tubes) across 25
PCR cycles (at 95C for 60 s, average primer 2 Tm for 60 s, and
74C for 60 s) following an initial step at 95C for 5 min. After
10 min at 74C, the PCR products were analyzed on agarose gels.
Topt was determined as described above, by 12 PCR reactions run
with the optimal buffer over a temperature gradient from average
primer 2 Tm  4C to average primer 2 Tm  11C.
LMPCR and ELMPCR.—The ampliﬁcation reactions were per-
formed in 100 ml optimal Taq buffer (10 mM Tris-HCl [pH 8.9],
40 mM NaCl, and 0.01% gelatin, supplemented with MgCl2 and
(NH4)2SO4 as indicated in table 1) containing 1.6 mg ligated DNA
(25 ml; see above), 10 pmol primer 2, 10 pmol (for LMPCR) or 30
pmol (for ELMPCR) linker-primer, 200 mM of each dNTP, and 3
U Taq polymerase (Amersham Biosciences), overlaid with 50 ml
mineral oil. PCR ampliﬁcation was performed for 22 cycles (for
LMPCR18) or 26 cycles (for ELMPCR), as follows: 1 cycle at 95C
for 300 s, Topt for 180 s, and 74C for 180 s; 1 cycle at 95C for
60 s, Topt  1C for 150 s, and 74C for 180 s; 1 cycle at 95C for
60 s, Topt  2C for 120 s, and 74C for 180 s; 1 cycle at 95C for
60 s, Topt  3C for 120 s, and 74C for 180 s; 1 cycle at 95C for
60 s, Topt  4C for 90 s, and 74C for 150 s; 13 (for LMPCR) or
17 (for ELMPCR) cycles at 95C for 60 s, Topt  4C for 90 s  5
s per cycle, and 74C for 150 s  5 s per cycle; 1 cycle at 95C
for 60 s, Topt  3C for 240 s, and 74C for 240 s; 1 cycle at 95C
for 60 s, Topt  2C for 240 s, and 74C for 240 s; 1 cycle at 95C
for 60 s, Topt  1C for 240 s, and 74C for 240 s; 1 cycle at 95C
for 60 s, Topt for 240 s, and 74C for 600 s; followed by a 4C hold.
Each reaction (100 ml) was stopped by addition of 25 ml of 2.5-M
NaCl and 60-mM EDTA (pH 8.0), followed by one phenol-chlo-
roform extraction (250 ml of 30:50), DNA precipitation with 2.5
volumes ethanol, centrifugation, and washing with 80% ethanol,
as described above. Air-dried DNA pellets were resuspended in 10
ml of sequencing gel loading buffer and were heated at 65C for
15 min. The DNA samples were heated at 95C for 2 min just
before analysis by gel electrophoresis (60-cm-long, 8% polyacryl-
amide-TBE [0.09-mM Tris-borate {10.8 g/liter Tris and 5.5 g/liter
boric acid} and 0.0025 EDTA {pH 8.0}] sequencing gels), elec-
troblotting to nylon membranes, and hybridization to 32P-radio-
labeled single-strand probes, by use of the same equipment and
methodology described by Drouin et al.18 After hybridization, the
membranes were washed once in 2# SSPE and 0.1% SDS at room
temperature for 15 min and once in 1# SSPE and 0.1% SDS at
55C for 15 min. After air drying, the membranes were exposed
in a PhosphorImager (Storm 860 [GE Healthcare]), and the signals
were analyzed with ImageQuant TL software (v2003.01 [Amer-
sham Biosciences/GE Healthcare]).
DNA cleavage mapping.—Nucleotide-resolution mapping of
DNA strand scissions was achieved by in-gel alignment of
(E)LMPCR signals with Maxam and Gilbert DNA sequencing lad-
ders after optimal reduction or magniﬁcation of signal intensity
and blowup of the gel region to be analyzed, to maximize band
resolution. Cleavage mapping was performed by at least two in-
vestigators and was conﬁrmed in at least three independent anal-
yses involving each duplicate ELMPCR reaction, and, in several
cases, different primer sets.
Most potential problems and recommendations regarding ge-
nomic sequencing by conventional LMPCR17,18 hold for ELMPCR.
Careful selection of primers (e.g., absence of repetitive DNA and
a melting temperature match) and optimization of PCR condi-
tions with the selected primers (see above) are of paramount im-
portance to maximize (E)LMPCR success rate. ELMPCR usually
requires three more PCR ampliﬁcation cycles than does LMPCR
to yield comparable signal intensities at 5′-P DNA cleavage sites
(e.g., restriction enzyme–mediated cleavages). This differencewas
primarily due to the ﬁvefold lower antilinker concentration in
ELMPCR compared with the linker concentration in LMPCR and
possibly also to the different blunt-end structures of the two link-
ers. In addition, it is not known whether there are potentially
negative effects of 5′-end–linked adducts on ligation efﬁciency.
The relative ELMPCR signal intensities measured at an in vivo
TOP2 cleavage site by use of serial twofold dilutions of cellular
DNA were linearly related to cleaved DNA concentration ( 2R p
) (ﬁg. 3), which showed that ELMPCR signal intensities can0.997
be used to evaluate relative extents of DNA cleavage at speciﬁc
sites.
Results
ELMPCR
In contrast to conventional LMPCR, which requires ge-
nomic 5′-P DNA termini for linker ligation, ELMPCR was
designed so that linker ligation does not depend on the
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Figure 4. Distinction of apoptotic versus TOP2-mediated DNA cleavage by combined use of ELMPCR and LMPCR. Human P6 lympho-
blastoid cells were treated or were not treated (controls) with VP-16 or with CD95 antibody (Ab) to induce apoptosis. Part of the cells
was then heat shocked (HS) at 60C for 15 min to reverse topoisomerase-mediated DNA cleavage before DNA extraction. ELMPCR and
LMPCR data are from duplicate cell cultures, by use of set 1 primers for noncoding-strand analysis (A) and set 2 primers for the coding-
strand analysis (B). The TOP2 cleavage site is at 6909/6910, and the apoptotic cleavage region (Ap) extends upstream of 6816 on the
noncoding strand (A) and downstream of 6816 on the coding strand (B) (see ﬁg. 9). The asterisk (*) in panel B indicates the expected
position for a reciprocal TOP2 cleavage, which was not detected, opposite to the TOP2 cleavage site identiﬁed on the coding strand.
TOP2 cleavage positions indicate 5′ nucleotides covalently linked to the enzyme. Lanes G and A are Maxam and Gilbert DNA sequencing
ladders. The ELMPCR and LMPCR exposure intensities were normalized to DNA sequencing ladders.
5′-end structures generated at DNA breaks. As shown be-
low, ELMPCR permits genomic mapping of topoisomer-
ase-mediated DNA strand breaks featuring enzyme-linked
5′ ends, such as those produced by type II and type IA
DNA topoisomerases. Because the topoisomerase tyrosine
residues (or oligopeptides) bound to the 5′-P termini can-
not be removed by proteinase K treatments used to extract
the DNA (see the “Material and Methods” section), these
blocked 5′-phosphates cannot be ligated to linkers and
thus cannot be detected by conventional LMPCR. The dis-
tinctive features of ELMPCR are illustrated in ﬁgure 1. The
central difference between ELMPCR and other LMPCR
methods is that ELMPCR targets direct ligation of an an-
tilinker to the 3′-hydroxyl terminus of a primer-extended
DNA molecule, instead of ligation of a conventional link-
er to a 5′-P terminus of genomic DNA (in LMPCR) or link-
er ligation to linearly ampliﬁed primer-extended single-
strand DNA19 or terminal transferase–elongated DNA.20
The antilinker nucleotide sequence is complementary to
that of the LMPCR linker, so that the same linker primer
can be used in both LMPCR and ELMPCR protocols. Note
also that the short antilinker oligonucleotide carries a
(2′,3′)-dideoxy cytidine at the 3′ end, to prevent inter-
antilinker ligation. Except for these intrinsic differences,
all PCR ampliﬁcation and subsequent steps are similar
in both procedures. The capacity of ELMPCR to detect
TOP2-mediated DNA cleavage and LMPCR-detectable
strand breaks had been validated using restriction en-
zyme–cleaved DNA and in vitro TOP2 DNA cleavage re-
actions (M. L. Fournier, personal communication, andA.T.
and M.-E.M., unpublished data). Because the same linker
primer can be used in LMPCR and ELMPCR, the combi-
nation of both techniques provides a unique way to di-
rectly distinguish, in the same sequencing gel, DNA strand
breaks yielding 5′-P from those producing non–5′-P ter-
mini, as demonstrated below.
Analysis of Topoisomerase-Mediated and Apoptotic DNA
Strand Cleavage across MLL Exon 12–Intron 12 Region
A combination of ELMPCR and LMPCR was used for ge-
nomic mapping of TOP2-mediated and apoptotic DNA
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Figure 5. Colocalization of etoposide- and teniposide-induced
TOP2 DNA cleavage. The legend is available in its entirety in the
online edition of The American Journal of Human Genetics.
Figure 6. Caspase-dependent nucleolytic cleavage, distinguished
from TOP1-mediated DNA cleavage. The legend is available in its
entirety in the online edition of The American Journal of Human
Genetics.
cleavage in the exon 12–intron 12 area, a genomic region
apparently exempt of t-AML–related chromosomal trans-
locations. EBV-immortalized B-lymphocytes (P6 cells)
were treated with etoposide for a short time (30 min) so
that etoposide-induced TOP2-mediated DNA cleavage
could be detected in the absence of signiﬁcant apoptotic
DNA cleavage. Longer treatments (6 h) were also admin-
istered, to assess apoptotic DNA cleavage, which follows
initial etoposide-mediated stabilization of TOP2-DNA
cleavage complexes. In contrast to fully viable untreated
cells, these treatments induced apoptosis and complete
loss of cell viability, as checked by ﬂow cytometry analysis
performed as described elsewhere.26 Combined use of the
two LMPCR procedures permitted distinction of DNA
strand breaks mediated by TOP2 (enzyme-linked 5′ ends)
from those resulting from apoptosis-related nucleolytic
cleavage that produces 5′-P termini. Representative ELM-
PCR cleavage patterns are presented in ﬁgure 4A, which
shows a major doublet TOP2 cleavage detected after 30
min of exposure to clinically relevant etoposide concen-
trations.27 This cleavage signal persisted after 6 h of ex-
posure, although at reduced intensity. Detection of this
cleavage was highly reproducible in multiple experiments
using different sets of primers and different cell types,
including human ﬁbroblasts and lymphoblastoid CEM
cells (see below), as well as T47D breast carcinoma cells
(not shown). Several lines of evidence indicate that this
cleavage was mediated by TOP2: (1) it was rapidly and
dose-dependently induced by etoposide (ﬁg. 4A) and was
produced at the same position in response to teniposide,
another speciﬁc and widely used TOP2 poison (ﬁg. 5); (2)
cleavage was reversible by heat shock, a characteristic fea-
ture of drug-stabilized TOP2 cleavage complexes1; and (3)
etoposide-induced strand cleavage at this site was strongly
reduced in a TOP2a-mutant CEM/VM-1 cell line deﬁcient
in TOP2 activity21,22 compared with in parental CEM cells
(see below). TOP2-mediated strand breaks were not de-
tected by LMPCR (ﬁg. 4A, right), as expected. In contrast,
clustered redundant strand breaks that were most evident
after 6 h of etoposide treatment were efﬁciently detected
by both LMPCR and ELMPCR. The similar pattern of
strand breaks induced by Fas receptor (CD95) antibody
(ﬁg. 4A), a classic inducer of apoptosis acting via receptor
activation and not DNA damage, and their suppression
by preincubation of the cells with the pan-caspase inhib-
itor zVAD-fmk (see below) indicate that they were medi-
ated by caspase-activated nucleases, apparently involved
in both Fas and DNA-damage apoptotic pathways. In con-
trast, TOP2-mediated cleavage was not affected by zVAD-
fmk. Figure 4B shows the corresponding ELMPCR and
LMPCR cleavage patterns detected with a set of primers
targeting the opposite (coding) strand of the exon 12 re-
gion. No TOP2-mediated cleavage was detected on this
strand after 30 min of exposure to etoposide (ﬁg. 4B), ad-
ministered at concentrations up to 100 mM (not shown).
Reciprocal TOP2 cleavage opposite to the TOP2 cleavage
site identiﬁed on the noncoding strand (ﬁg. 4A) was not
detected. However, strong DNA cleavage clustered in two
adjacent hotspots was detected by both ELMPCR and
LMPCR after 6 h of drug exposure, which validated the
ELMPCR capacity to detect strand breaks with this set of
primers. This multiple cleavage was apoptosis related and
caspase dependent, since it was induced by anti-CD95 an-
tibody (ﬁg. 4B) and was completely suppressed by zVAD-
fmk (ﬁg. 6). Although the ELMPCR and LMPCR patterns
were very similar, minor differences were observed in rel-
ative signal intensities in the upper part of the respective
apoptotic cleavage patterns, which are thought to reﬂect
a statistical effect of the larger number of DNA strand
breaks detected by ELMPCR. Of note, heat treatment of
the cells to revert TOP2-mediated DNA cleavage caused a
visible shift of the upper (E)LMPCR bands toward smaller
products, probably reﬂecting heat-mediatedenhancement
of an endogenous DNA degradation process associated
with apoptosis.
Human primary ﬁbroblasts and T-lymphoblastoid CEM
cells treated with etoposide produced DNA cleavage pat-
terns very similar to those obtained using P6 cells (ﬁgs. 7
and 8 and data not shown). These cells were also exposed
to CPT, a TOP1 poison, which stabilizes single-strand
breaks (SSBs) in TOP1 cleavage complexes yielding en-
zyme-linked 3′ ends and 5′-hydroxyl termini.2 Showing
that ELMPCR can be used for genomic mapping of TOP1
cleavage sites was relevant because it has been suggested
that TOP1-mediated DNA cleavage might contribute to
apoptotic DNA cleavage.28,29 CPT-induced TOP1-mediated
strand scissions, not directly detectable by LMPCR, were
thus mapped by ELMPCR in the MLL translocation-prone
region and served as positive controls for strand-break de-
tection, in case TOP2-mediated cleavage was not detected.
Figure 7 shows the ELMPCR results obtained using pri-
mary human ﬁbroblasts treated with etoposide or CPT for
1 h. Etoposide produced a major heat-reversible TOP2-
mediated DNA cleavage at a unique doublet site on the
noncoding strand (ﬁg. 7A), identical to that found in P6
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Figure 7. ELMPCR detection of TOP1- and TOP2-mediated DNA
cleavage in primary human ﬁbroblasts. Conﬂuent ﬁbroblast cultures
were treated or were not treated (controls) with VP-16 (50 mM)
or CPT (10 mM) for 1 h. Part of the cells was then heat shocked
(HS), to reverse topoisomerase-mediated DNA cleavage. ELMPCR
data were from duplicate cell cultures, by use of set 1 primers for
the noncoding strand (A) and set 2 primers for the coding strand
(B). A stronger exposure of the bottom part of panel B is shown
below it, to enlarge the signal of a weak TOP2-mediated cleavage.
Cleavage sites are at 6909/6910 for TOP2 and 6822/6823/6824
and 6920/6921 for TOP1 on the noncoding strand and at 6891/
6892 and 6811/6812 for TOP1 on the coding strand (see ﬁg. 9
map). TOP2 and TOP1 cleavage positions indicate the nucleotides
covalently linked to the enzyme (5′-linked TOP2 and 3′-linked
TOP1). Lanes G and A are Maxam and Gilbert DNA sequencing
ladders.
cells (ﬁg. 4A). No reciprocal cleavage was detected on the
opposite (coding) strand, as in P6 cells. However, a heat-
reversible TOP2 cleavage was detected 11–12 bp down-
stream of the expected reciprocal cleavage site (ﬁg. 7B).
ELMPCR revealed several CPT-induced SSBs, which could
be reversed by 30-min cell recovery in the absence of drug
(ﬁg. 7A and 7B) or by heat shock (not shown). In addition,
an unrelated cleavage ladder of weak signal intensity was
observed in ﬁbroblasts growing in the absence of drug,
visible at the bottom of ﬁgure 7A and in the middle of
ﬁgure 7B. Similar cleavage was enhanced by apoptosis in
P6 cells (ﬁg. 4A and 4B) and was unexpectedly strong in
conﬂuent healthy ﬁbroblast cultures (A.T. and M.-E.M.,
unpublished data).
As shown in ﬁgure 8A and 8B, reciprocal double-strand
DNA cleavage produced by the restriction enzyme ApoI
was used as a positive control in the search for reciprocal
TOP2-mediated DNA cleavage opposite to themajor TOP2
site 6909/6910 in response to etoposide poisoning. An
ApoI cleavage site was located 12 nt upstream of the dou-
blet TOP2 cleavage site. This endonuclease generates 3′-
recessed 4-base staggered double-strand cuts similar to
reciprocal cleavage by TOP2. ELMPCR performed with a
0.6% dilution of ApoI-cleaved CEM DNA (extensive cleav-
age to completion) yielded cleavage signals of intensity
comparable to that of the signals produced in vivo by
TOP2 (ﬁg. 8A). Similar ELMPCR results were obtainedwith
Pfu exo- or Sequenase-mediated (GE Healthcare Life Sci-
ences) primer extension, conﬁrming that no etoposide-
induced cleavage could be detected on the other strand
at the position expected for a reciprocal TOP2 cleavage
opposite to site 6909/6910, in contrast to positive detec-
tion of reciprocal ApoI cleavage with Pfu exo- or Sequen-
ase-mediated primer extension, or Sequenase-ﬁlled 3′-
recessed termini instead of primer extension (ﬁg. 8B). The
unexpected shorter ApoI cleavage products seen in ﬁgure
8A and 8B apparently reﬂect some contaminating nucleo-
lytic activity present in the commercial ApoI preparation,
since they did not occur in partial ApoI cleavage reactions
(A.T., unpublished data).
Supportive evidence that the DNA cleavage detected at
site 6909/6910 was mediated by TOP2 is provided by the
ELMPCR results presented in ﬁgure 8C. Teniposide-resis-
tant CEM/VM-1 cells, which are deﬁcient in TOP2a activ-
ity21 because of a single base substitution–altering enzyme
interaction with ATP,22 showed strongly reduced DNA
cleavage at site 6909/6910 in response to etoposide,
compared with parental CEM cells expressing wild-type
TOP2a. Cleavage at this site was thus predominantly me-
diated by TOP2a in CEM cells, whereas that observed in
VM-1 cells probably resulted from normal TOP2b and/or
residual TOP2a activity. In contrast, a similar extent of
heat-reversible DNA cleavage was observed in VM-1 and
CEM cells at a nearby TOP2 site located on the opposite
strand (6917/6918) in response to 100-mMetoposide treat-
ments for 60 min. The latter observation leads us to spec-
ulate that cleavage at this second TOP2 site was predom-
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Figure 8. TOP2-mediated DNA cleavage in CEM and TOP2a-mutant CEM/VM-1 cells. Cells were treated with 25 mM or 100 mM (indicated
by larger plus sign []) VP-16 or 5 mM CPT for 30 min. ELMPCR was performed with equal amounts of DNA isolated from duplicate
drug-treated cell cultures or from untreated cultures including 0.6% CEM DNA cleaved to completion by restriction endonuclease ApoI.
A and B, ELMPCR with primer extension (ext.) performed with Pfu exo (P) or Sequenase (S) or PCR ampliﬁcation after Sequenase-
mediated ﬁlling of 3′-recessed termini (with no heat denaturation and no primer 1 extension) and antilinker ligation (B), by use of
set 1 primers (A) or set 10 primers (B). In panel C, set 1 primers were used. The noncoding-strand cleavage sites for TOP2, TOP1, and
ApoI are 6909/6910, 6920/6921, and 6897, respectively. No reciprocal TOP2 cleavage was detected on the coding strand (TOP2* at
6906/6907).
inantly mediated by TOP2b, which is not affected in VM-1
cells.
Colocalization of Topoisomerase-Mediated and Apoptotic
DNA Strand Cuts at a Major MLL Translocation Hotspot
DNA cleavage analysis was then focused on the intronic
region upstream of MLL exon 12, where therapy-related
leukemia translocation breakpoints are unusually clus-
tered across a very short region (∼10 bp)11,30,31 (ﬁg. 9). Fig-
ure 10 displays ELMPCR data covering a region including
the translocation hotspot and the exon 12 apoptotic cleav-
age region. A striking ﬁnding is the quasi colocalization
of TOP1, TOP2, and apoptotic cleavage sites within the
translocation hotspot, at the upstream extremity of the
intronic apoptotic cleavage region (ﬁg. 9). After 30 min
of etoposide exposure, a heat-reversible TOP2 (doublet)
cleavage was reproducibly detected on the coding strand
at position 6583/6584, a few nucleotides upstream of a
major CPT-TOP1 cleavage site located within the trans-
location hotspot (ﬁg. 10B). No TOP2-mediated DNA cleav-
age was detected on the opposite strand. Three reversible
CPT-TOP1 cleavage sites were identiﬁed on the noncoding
strand, all located in apoptotic cleavage regions (ﬁg. 10A).
Remarkably similar apoptotic cleavage patterns were pro-
duced in cells incubated for 6 h with CD95 antibody, eto-
poside, or CPT. All strand scissions induced in the apo-
ptotic cleavage regions were apparently mediated by
caspase-activated nucleases, since they were completely
suppressed by zVAD-fmk (ﬁg. 6).
DSBs are dangerous DNA lesions that can cause cell
death or promote illegitimate DNA recombination events
in surviving cells. The possible production of DSBs in the
upstream apoptotic cleavage region was assessed by
LMPCR ampliﬁcation by use of cellular DNA from eto-
poside-treated cells (6 h of treatment) directly ligated to
LMPCR linker or ELMPCR antilinker (without primer ex-
tension). The data shown in ﬁgure 10C demonstrate the
occurrence of multiple blunt DSBs and potential staggered
DSBs, several of which were localized within or close to
the translocation hotspot (ﬁg. 9). In sharp contrast, similar
formation of multiple DSBs was not observed in themajor
downstream apoptotic cleavage region (exon 12), where
no therapy-related translocation breakpoints have been
reported.
Discussion
We describe here a novel LMPCR procedure, ELMPCR,
which allows direct mapping of in vivo topoisomerase-
mediated DNA strand breaks in single-copy genes at nu-
cleotide resolution. We present the ﬁrst nucleotide-reso-
lution map integrating in vivo TOP2- and TOP1-mediated
strand breaks and apoptotic DNA cleavages in a human
gene segment, illustrating the potential of this method.
This high-resolution map across both translocation-prone
and translocation-exempt regions of MLL reveals several
ﬁndings of interest with regard to the nature of the re-
spective DNA cleavages and their position relative to
known translocation breakpoints.
All but one of the TOP2-mediated strand breaks were
localized relatively far from the translocation hotspot,
with the dominant TOP2 cleavage site located 1300 bp
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Figure 9. Nucleotide-resolution map of topoisomerase DNA cleavage sites, apoptotic cleavage hotspots, and translocation breakpoints.
The map integrates the results of multiple ELMPCR and LMPCR analyses performed as described in ﬁgures 4, 7, 8, and 10, by use of all
sets of primers listed in table 1. The coding strand is the upper strand. Blue arrows, Etoposide-induced TOP2 cleavage sites. Green
arrows, CPT-induced TOP1 cleavage sites. Hotspots for apoptotic cleavage are shown underlined in red (thick line indicates stronger
cleavage). Red arrows, Predominant cleavage sites (thick arrows indicate stronger cleavage sites). Asterisks (*) indicate blunt DSBs.
The black box deﬁnes a major translocation hotspot, which includes nine therapy-related translocation breakpoints associated with
multidrug treatments involving TOP2-targeted drugs,11,30,31,32 and the breakpoint reported for a cell line (SN-1) derived from a patient
with T-cell acute lymphoblastic leukemia with no history of previous treatment.32 Vertical marks show additional translocation breakpoints
reported in the literature,30,31,33,34 with each color corresponding to a different patient, except for all orange breakpoints, which resulted
from Fas-mediated apoptosis in vitro.35,16 Duplicate marks of same color reﬂect uncertainties about the exact MLL breakpoint location
because of local overlapping of DNA sequences at the MLL-partner junction or because of sequence gaps between derivative MLL and
derivative partner breakpoints.
downstream, in exon 12 (or exon 9 according to an older
numbering system). This observation does not support a
potential involvement of these sites as direct triggers of
MLL translocations. To our knowledge, no translocation
breakpoints have been reported near the dominant TOP2
cleavage sites mapped in exon 12. Of interest, these TOP2
cleavage sites were located in a translocation-exempt re-
gion covering most of exon 12 and downstream intron
12 sequences. In contrast, one TOP2 cleavage site detected
at the border of the t-AML translocation hotspot might
be at the origin of the MLL/AF-9 translocation breakpoint
junction reported by Whitmarsh et al.11 The very close
proximity of this TOP2 site to multiple apoptotic DNA
cleavages observed at and near the translocation hotspot
is consistent with potential interactions between TOP2
and caspase-activated DNase(s)36 and with a possible role
of TOP2 as translocation initiator at this site.11 ELMPCR
mapping of in vivo TOP2 cleavage sites and apoptotic
DNA scissions in AF-9 and other known MLL fusions, in-
cluding novel partner genes identiﬁed by long-distance
inverse PCR,37 should help assess the respective role of
TOP2 and apoptotic DNA fragmentation in t-AML–asso-
ciated leukemogenic translocations.
Of interest, none of the in vivo TOP2 cleavage sites iden-
tiﬁed here were found to correspond to in vitro–deter-
mined consensus TOP2 cleavage sequences reported in
exon 12 (6857–687438,39). Thus, the best-ﬁt matches to pu-
tative consensus sequences are poor predictors of bona
ﬁde cellular TOP2 cleavage sites. Moreover, no DNA cleav-
age was observed at these cellular TOP2 cleavage sites in
reactions performed in vitro with human TOP2a and
DNA isolated from CEM cells or PCR-ampliﬁed MLL DNA
(A.T. and M.-E.M., unpublished data). These observations
strongly suggest that local chromatin structure and DNA
accessibility are the primary determinants of TOP2 cleav-
age site speciﬁcity in vivo, as proposed elsewhere.13,14 If
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Figure 10. Colocalization of apoptotic and topoisomerase-
mediated DNA cleavages at a major MLL translocation hotspot. CEM
cells were treated with etoposide (100 mM), CPT (5 mM), or CD95
antibody (Ab) for the time indicated. ELMPCR data were from du-
plicate cell cultures, by use of set 7 primers for noncoding-strand
cleavage analysis (A) and set 4 primers for coding-strand analysis
(B). The upper panel in A shows a lower exposure of the top portion
of the main panel. Cleavage sites are 6822/23, 6801, and 6626/
27 for TOP1 on the noncoding strand (A) and 6588/89 for TOP1
and 6583/84 for TOP2 on the coding strand (B). C, Detection of
blunt DSBs by direct PCR ampliﬁcation after linker or antilinker
ligation (no heat denaturation and no primer 1 extension), as
compared with LMPCR (left) or ELMPCR (right), respectively. The
apoptotic cleavage regions (Ap) extend from 6816–6773 (top) and
6633–6585 (bottom) on the noncoding strand (A), and from 6633–
6595 on the coding strand (B); an asterisk (*) indicate cleavages
forming a major blunt DSB at 6602/6603. The TH side boxes locate
the translocation hotspot (ﬁg. 9). Lanes G and A are Maxam and
Gilbert DNA sequencing ladders. HS p heat shocked.
so, local in vivo TOP2 cleavage site speciﬁcity and fre-
quency might differ in different cell types, depending on
the differentiation state and associated chromatin struc-
ture at the investigated site. Although the dominant in
vivo TOP2 cleavage sites observed in this study were lo-
cated at identical positions in several unrelated cell types,
it is possible that the chromatin context of theMLL intron
11–exon 12 region in these cells may differ from that pre-
vailing in the leukemogenic precursor cells in which the
t-AML translocations occur, whose identity is usually
unknown. It will thus be important to identify these leu-
kemogenic precursor cells for future studies of the rela-
tionships between localized chromatin structure, apopto-
tic and TOP2-mediated DNA cleavage, and translocation
breakpoints.
The observation that etoposide treatments produced
predominantly TOP2-mediated SSBs in theMLL region an-
alyzed, regardless of the cell type investigated, is of inter-
est, considering that normal TOP2 function (no inhibitor)
involves transient cleavage of both DNA strands.1,2 Our
ELMPCR results are consistent with those of previous stud-
ies reporting predominant formation of SSBs in cultured
cells exposed to etoposide1,40 and in TOP2 cleavage reac-
tions performed in vitro at low drug concentrations.41 The
single-strand scissions detected here may reﬂect the asym-
metric action of an individual etoposide molecule stabi-
lizing one strand-speciﬁc nick, with little drug effect on
TOP2 cleavage/religation of the opposite DNA strand
scission.41,42 With regard to recombination potential, one
should keep in mind that TOP2-mediated SSBs may be
converted to DSBs by collisions with replication forks or
transcription complexes, similar to trapped TOP1 cleavage
complexes.2,43,44
The strongest apoptotic DNA cleavage across the MLL
gene region investigated occurred in exon 12, in all cell
types investigated. This major apoptotic cleavage region
would include the MLL site-speciﬁc cleavage reported
elsewhere15,38 and the colocalized in vivo TOP2 cleavage
and DNase I hypersensitive sites mapped at lower reso-
lution by Southern analysis45,46 (exon 9 in those studies
corresponds to exon 12 in the present study47). The ap-
optotic cleavage pattern observed here at nucleotide res-
olution in exon 12 is peculiar and quite distinct from that
produced in the upstream intronic region containing the
translocation hotspot (ﬁg. 9). The exon 12 cleavage pat-
tern might reﬂect an initial endonucleolytic cleavage fol-
lowed by 5′r3′ exonucleolytic processing of each strand.
This apparent double-strand cleavage site is located at
the dyad symmetry center of an inverted repeat, 5′-
TTGTGN8CACAA, a structure thatmight provide potential
binding sites for DNA cleaving enzyme(s), including
TOP1, found to cleave both 5′-TTGTG motifs (on opposite
strands) in response to CPT poisoning. A future challenge
will be to determine which apoptotic nucleases may cause
the observed zVAD-fmk–sensitive DNA degradation pro-
cess. Of interest, the unique potential double-strand cleav-
age site detected in this apoptotic cleavage region was
found to precisely correspond to one MLL translocation
breakpoint at site 6816 observed in cultured cells engaged
in Fas receptor–mediated apoptosis.16 Three additional
Fas-induced translocation breakpoints35 were also local-
ized within apoptotic DNA cleavage regions (ﬁg. 9), sup-
porting the view that repair of an initial (or partial) ap-
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optotic DNA cleavage by nonhomologous end joining33
may produce chromosomal translocations in viable cells
escaping irreversible apoptotic execution.15,16,35,48 The oc-
currence of multiple nicks, potential staggered DSBs, and
blunt cuts detected in theminor apoptotic cleavage region
harboring the t-AML breakpoint cluster suggests that such
DNA lesions, undergoing variable extents of DNA re-
pair,32,33,35 are likely to be at the origin of these translo-
cations. Intronic illegitimate recombination of MLL with
one of many potential gene partners, after DNA cleavage
and attempted repair, would favor formation of in-frame
fusion leukemogenic oncogenes.7,9,32,49 Expression of on-
cogenes conferring tumor-cell growth advantage is likely
to play amajor role in selecting breakpoints that lie within
an intron rather than within an exon. Although apoptotic
DNA cleavage, per se, apparently can be a sufﬁcient con-
dition to produce MLL/AF9 translocations in cultured
cells,16 another mechanism is required to explain why t-
AML balanced translocations are preferentially associat-
ed with chemotherapeutic treatments involving TOP2-
targeted drugs3,4,6 but not with any cytotoxic agent. It thus
will be important to determine whether TOP2-mediated
DNA cleavage can induce illegitimate recombination
events at translocation hotspots in MLL and relevant tar-
get gene partners in the absence of apoptotic DNA cleav-
age. Second, it will be important to determine whether
TOP2 poisoning or catalytic inhibition may indirectly
stimulate DSB formation at such sites in surviving cells.
For example, initial apoptotic cleavage of higher-order
chromatin loops by a caspase-activated DNase might be
triggered by alteration(s) of DNA/chromatin structure or
chromatin remodeling resulting from TOP2 dysfunction.
The striking association of CPT and TOP1 cleavage sites
with apoptotic DNA cleavage regions is intriguing. It may
be related to the suggestion that TOP1-mediated DNA
cleavage can contribute to chromatinolysis in apopto-
sis.29,50 Although most SSBs induced by CPT in the present
study did not correspond to apoptotic DNA cleavage sites
mapped in this MLL region, it remains possible that some
of the zVAD-fmk–sensitive DNA cleavages observed in eto-
poside-treated cells could have been mediated by TOP1
after recruitment or activation consequent to single-strand
DNA cleavage induced by caspase-activated nucleases.51
ELMPCR is, to our knowledge, the ﬁrst PCR-based tech-
nique used successfully to map in vivo TOP2-mediated
DNA cleavage in single-copy genes at single-nucleotide
resolution. Previous analyses of drug-induced TOP2 cleav-
age sites in living cells were based on genomic primer-
extension techniques and were restricted to satellite DNA
repeats and multicopy genes, because of their intrinsi-
cally limited detection capacity.14,52 In principle, ELMPCR
should be suitable to map any topoisomerase-mediated
strand break, including TOP3-mediated DNA cleavage and
meiosis-speciﬁc DSBs catalyzed by TOP2-like Spo11 family
proteins, which also involve enzyme-linked 5′ ends.2,53 In
addition, ELMPCR provides a potential new tool for map-
ping other types of DNA lesions producing, directly or
indirectly, strand breaks with non–5′-P termini.
The observation of ELMPCR cleavage doublets at several
cellular TOP2 and TOP1 cleavage sites is intriguingbecause
DNA strand scissions produced in vitro by TOP2 or various
restriction enzymes were essentially detected as single-
nucleotide cleavage positions by ELMPCR (M. Fournier,
personal communication, and A.T. and M.-E.M., unpub-
lished data), thus ruling out a trivial artifact intrinsic to
the technique. Further work will be required to clarify the
origin of the apparent TOP2 cleavage degeneracy observed
in this and other studies52 and to determine whether this
phenomenon reﬂects some topoisomerase ﬂexibility with
regard to in vivo cleavage site speciﬁcity.
In summary, the work reported here validates the ex-
perimental potential of ELMPCR for genomic mapping of
topoisomerase-mediated DNA cleavage. The nature and
relative distribution of the observed cleavages with regard
to t-AML translocation breakpoints suggest that several
DNA cleaving mechanisms, including topoisomerase poi-
soning and apoptotic nuclease(s), may interact to produce
DSBs at sites prone to recombination events. The locali-
zation and remarkable clustering of some t-AML break-
points cannot be simply explained by the observed DNA
cleavage patterns but might result from potential inter-
actions between TOP2 poisoning, apoptotic DNA cleav-
age, and DNA repair attempts at speciﬁc sites of higher-
order chromatin structure.
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